natgillin/translations-raw huggingface dataset:
Elvitegravir (antacid suspension after ± 2 hours): 
elvitegravir (suspenzija antacida po ± 2 urah):
• In children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities. 
• pri otrocih, starih od 6 let, s telesno maso vsaj 25 kg, pri katerih alternativni režimi niso primerni zaradi toksičnosti.
Non-black 
Ne-črnci
However, a large amount of data on pregnant women (more than 1,000 exposed outcomes) indicate no malformative nor foetal/neonatal toxicity associated with emtricitabine. 
Vendar pa velika količina podatkov o nosečnicah (več kot 1.000 izidov izpostavljenih nosečnosti) ne kaže na malformacijsko ali feto/neonatalno toksičnost, povezano z emtricitabinom.
Changes in lipid laboratory tests 
Spremembe laboratorijskih preiskav lipidov
• low red blood cell count (anaemia) 
• nizko število rdečih krvnih celic (anemija)
There are no adequate and well-controlled studies of Genvoya or its components in pregnant women. 
Ni ustreznih, dobro kontroliranih študij z zdravilom Genvoya ali njegovimi učinkovinami pri nosečnicah.
Although there were no new safety issues identified, the implications of increased emtricitabine exposure remain uncertain (see sections 4.8 and 5.2). 
Čeprav niso prepoznali novih vprašanj glede varnosti, so implikacije večje izpostavljenosti emtricitabinu negotove (glejte poglavji 4.8 in 5.2).
When treating HIV infection, it is not always possible to tell whether some of the unwanted effects are caused by Genvoya or by other medicines that you are taking at the same time, or by the HIV disease itself. 
Pri zdravljenju okužbe z virusom HIV ni vedno mogoče povedati, ali nekatere od naštetih neželenih učinkov povzroča zdravilo Genvoya ali druga zdravila, ki jih jemljete sočasno, ali sama bolezen HIV.
If you feel dizzy when taking Genvoya, do not drive or ride a bicycle and do not use any tools or machines. 
Če se vam med zdravljenjem z zdravilom Genvoya pojavlja omotičnost, ne vozite avtomobila, ne kolesarite in ne upravljajte orodij ali strojev.
Careful dose titration of the antidepressant and monitoring for antidepressant response is recommended. 
Priporoča se skrbno titriranje odmerka antidepresiva in spremljanje odziva na antidepresiv.
With other sedatives/hypnotics, dose reduction may be necessary and concentration monitoring is recommended. 
Pri drugih sedativih/hipnotikih bo morda treba odmerek zmanjšati, priporoča pa se spremljanje koncentracij.
Possible serious side effects: tell a doctor immediately 
Možni resni neželeni učinki: takoj obvestite svojega zdravnika
The mean age was 48 years (range 23-64). 
Povprečna starost je bila 48 let (razpon 23-64).
No data are available to make dose recommendations in children aged less than 12 years with renal impairment or in children less than 18 years with end stage renal disease. 
Ni podatkov, na podlagi katerih bi podali priporočila o odmerjanju pri otrocih, mlajših od 12 let, z ledvično okvaro ali pri otrocih, mlajših od 18 let s končno ledvično odpovedjo.
Selective serotonin reuptake inhibitors (SSRIs) Escitalopram 
selective serotonin reuptake inhibitors) escitalopram
Table 1: Interactions between the individual components of Genvoya and other medicinal products 
Preglednica 1: Interakcije med posameznimi učinkovinami zdravila Genvoya in drugimi zdravili
INR should continue to be monitored during the first weeks following ceasing treatment with Genvoya. 
INR je treba še naprej spremljati prve tedne po prenehanju zdravljenja z zdravilom Genvoya.
Look out for any symptoms of infection or other symptoms such as: muscle weakness weakness beginning in the hands and feet and moving up towards the trunk of the body palpitations, tremor or hyperactivity. 
Bodite pozorni na kakršne koli simptome okužbe ali druge simptome, kot so: oslabelost mišic oslabelost, ki se začne v dlaneh in stopalih in se premika proti trupu razbijanje srca (palpitacije), tresavica ali hiperaktivnost
The substantial reduction in elvitegravir exposure may result in virological failure and an increased risk of mother-to-child transmission of HIV infection. 
Pomembno zmanjšanje izpostavljenosti elvitegravirju lahko povzroči virološki neuspeh in povečano tveganje za prenos okužbe s HIV z matere na otroka.
Clinical monitoring is recommended due to the potential for hyperkalaemia. 
Priporočeno je klinično spremljanje zaradi možnosti hiperkaliemije.
Study GS-US-292-1515 
Študija GS-US-292-1515
Treatment of overdose with Genvoya consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. 
Zdravljenje prevelikega odmerka z zdravilom Genvoya načeloma predstavljajo podporni ukrepi, vključno s spremljanjem vitalnih znakov in opazovanjem kliničnega stanja bolnika.
As a result, the amounts of Genvoya or other medicines in your blood may be affected. 
To lahko posledično vpliva na količino zdravila Genvoya ali drugih zdravil v vaši krvi.
Assessment of adverse reactions is based on safety data from across all Phase 2 and 3 studies in which 2,396 patients received Genvoya and from post-marketing experience. 
Ocena neželenih učinkov temelji na podatkih o varnosti iz vseh študij faze 2 in 3, v katerih je 2.396 oseb prejemalo zdravilo Genvoya, ter iz izkušenj v obdobju trženja.
Stopping Genvoya can seriously affect your response to future treatment. 
Prenehanje jemanja zdravila Genvoya lahko resno vpliva na vaš odziv na prihodnje zdravljenje.
Children aged 8 to < 12 years, > 25 kg 
Otroci, stari 8 do < 12 let, > 25 kg
2T = second trimester; 3T = third trimester; PP =postpartum a paired comparisons b P<0.10 compared with postpartum 
2T = drugi trimester; 3T = tretji trimester; PP = poporodno obdobje a sparjene primerjave b P < 0,10 v primerjavi s poporodnim obdobjem
For patients who are unable to swallow the tablet whole, the tablet may be split in half and both halves taken one after the other, ensuring that the full dose is taken. 
Za bolnike, ki ne morejo pogoltniti cele tablete, se lahko tableto prepolovi, vendar morajo bolniki vzeti obe polovici eno za drugo, da prejmejo celoten odmerek.
• heart medicines, such as: 
• zdravila za srce, kot so:
• alpha 1-adrenoreceptor antagonists: alfuzosin 
• antagonisti adenoreceptorja alfa 1: alfuzosin
Do not give this medicine to children aged 5 years or under, or weighing less than 25 kg regardless of age. 
Tega zdravila ne dajajte otrokom, starim 5 let ali manj, ali s telesno maso manj kot 25 kg, ne glede na starost.
Ex vivo binding of tenofovir alafenamide to human plasma proteins in samples collected during clinical studies was approximately 80%. 
Ex vivo vezava tenofoviralafenamid na humane plazemske proteine v vzorcih, odvzetih med kliničnimi študijami, je bila približno 80 %.
It is recommended that you do not breast-feed to avoid passing the virus to the baby in breast milk. 
Priporočljivo je, da ne dojite, da s tem preprečite prenos virusa preko mleka na dojenčka.
You should not take Genvoya with medicines containing: 
Zdravila Genvoya ne smete jemati z zdravili, ki vsebujejo:
The safety profile in paediatric patients who received treatment with Genvoya was similar to that in adults. 
Varnostni profil pri pediatričnih bolnikih, ki so prejemali zdravljenje z zdravilom Genvoya, je bil podoben kot pri odraslih.
It is important not to stop taking Genvoya without talking to your doctor: see section 3, Do not stop taking Genvoya. 
Pomembno je, da zdravila Genvoya ne prenehate jemati, ne da bi se pogovorili z zdravnikom: glejte poglavje 3, Ne prenehajte jemati zdravila Genvoya.
What Genvoya is and what it is used for 
Kaj je zdravilo Genvoya in za kaj ga uporabljamo
A cumulative review of all cases related to suicide-related events showed a total of 42 valid cases reporting 48 suicide-related events for Genvoya (13 from spontaneous, 29 from clinical trials). 
Kumulativni pregled vseh primerov, povezanih z dogodki v povezavi s samomorom, je pokazal skupno 42 veljavnih primerov poročanj o 48 dogodkih v povezavi s samomorom za zdravilo Genvoya (13 je bilo spontanih, 29 iz kliničnih preskušanj).
Emtricitabine can be removed by haemodialysis, which removes approximately 30% of the emtricitabine dose over a 3 hour dialysis period starting within 1.5 hours of emtricitabine dosing. 
Emtricitabin se lahko odstrani s hemodializo, ki odstrani približno 30 % odmerka emtricitabina v 3 urah dialize, če se začne v 1,5 ure po odmerjanju emtricitabina.
Aromatic and aliphatic hydroxylation or glucuronidation metabolites are present in very low levels, displaying considerably lower antiviral activity against HIV-1 and do not contribute to the overall antiviral activity of elvitegravir. 
Aromatski in alifatski presnovki hidroksilacije ali presnovki glukuronidacije so prisotni v zelo nizkih ravneh, kar kaže na znatno nižjo protivirusno aktivnost proti HIV-1 in ne prispeva k splošni protivirusni aktivnosti elvitegravirja.
Three patients had virologic failure at Week 48; there was no virologic resistance detected to Genvoya. 
Trije bolniki so imeli virološki neuspeh v 48. tednu; virološke rezistence na zdravilo Genvoya niso odkrili.
 If you notice the side effects described above, tell your doctor immediately. 
 Če opazite zgoraj opisane neželene učinke, takoj obvestite svojega zdravnika.
If you have hepatitis B infection, liver problems may become worse after you stop taking Genvoya. 
Če imate okužbo s hepatitisom B, se lahko težave z jetri poslabšajo, ko prenehate jemati zdravilo Genvoya.
5 This study was conducted using Genvoya. 
5 Ta študija je bila opravljena z zdravilom Genvoya.
The adverse reactions in Table 2 are listed by system organ class and frequency. 
Neželeni učinki v preglednici 2 so našteti po organskih sistemih in pogostnosti.
Medicines used in treating hepatitis B infection: 
Zdravila, ki se uporabljajo za zdravljenje okužbe s hepatitisom B:
• suicidal thoughts and suicide attempt (in patients who have had depression or mental health problems before), depression 
• samomorilne misli in poskus samomora (pri bolnikih, ki so že imeli depresijo ali težave z duševnim zdravjem), depresija
Alternative endothelin receptor antagonists may be considered. 
Razmisli se lahko o drugih antagonistih receptorjev endotelina.
Pooled treatment outcomes at 48 and 144 weeks are shown in Table 3. 
Združeni izidi zdravljenja v 48. in 144. tednu so prikazani v preglednici 3.
Study GS-US-292-0106 
Študija GS-US-292-0106
EVG = elvitegravir; COBI = cobicistat; FTC = emtricitabine; TAF = tenofovir alafenamide fumarate; TFV = tenofovir N/A = not applicable 
EVG = elvitegravir; COBI = kobicistat; FTC = emtricitabin; TAF = tenofoviralafenamidijev fumarat; TFV = tenofovir n/v = ne velja
In clinical studies of Genvoya, increases in serum creatinine occurred by Week 2 of treatment and remained stable through 144 weeks. 
V kliničnih študijah z zdravilom Genvoya se je pojavilo zvišanje serumskega kreatinina do 2. tedna zdravljenja in je ostalo stabilno do konca 144. tedna.
If you have both HIV infection and hepatitis B, it is especially important not to stop your Genvoya treatment without talking to your doctor first. 
Če ste okuženi tako z virusom HIV kot s hepatitisom B, je še zlasti pomembno, da ne prenehate z zdravljenjem z zdravilom Genvoya, ne da bi se prej posvetovali z zdravnikom.
Cmin: N/A 
Cmin: n/v
ANTICOAGULANTS Dabigatran 
ANTIKOAGULANTI dabigatran
Co-administration with medicinal products that are substrates of P-gp, BCRP, OATP1B1 and OATP1B3 may result in increased plasma concentrations of these products. 
Sočasno dajanje z zdravili, ki so substrati P-gp, BCRP, OATP1B1 in OATP1B3 lahko povzroči zvišanje koncentracij teh zdravil v plazmi.
The use of Genvoya in children aged 5 years or under has not yet been studied. 
Uporabe zdravila Genvoya pri otrocih, starih 5 let ali manj, še niso preučili.
Clinical data 
KLINIČNI PODATKI
The median terminal plasma half-life of elvitegravir following administration of E/C/F/TDF is approximately 12.9 hours. 
Mediani končni razpolovni čas elvitegravirja v plazmi po uporabi E/C/F/TDF je približno 12,9 ur.
bosentan and tadalafil 
bosentan in tadalafil
Each tablet contains 61 mg lactose (as monohydrate). 
Ena tableta vsebuje 61 mg laktoze (v obliki laktoze monohidrata).
Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice. 
Bolniki z že obstoječo jetrno disfunkcijo, vključno s kroničnim aktivnim hepatitisom, imajo v času kombinirane protiretrovirusne terapije (CART- combination antiretroviral therapy) več anomalij jetrne funkcije in jih je treba nadzirati v skladu s standardno prakso.
Contents of the pack and other information What Genvoya contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Genvoya
Disopyramide Flecainide Systemic lidocaine Mexiletine Propafenone 
dizopiramid flekainid sistemski lidokain meksiletin propafenon
• antacids, used to treat heartburn or acid reflux (see also section 3, How to take Genvoya). 
• antacide, ki se uporabljajo za zdravljenje zgage ali refluksa kisline (glejte tudi poglavje 3 Kako jemati zdravilo Genvoya).
Genvoya should be taken orally, once daily with food (see section 5.2). 
Zdravilo Genvoya se jemlje enkrat dnevno, peroralno s hrano (glejte poglavje 5.2).
Pharmacotherapeutic group: Antivirals for systemic use; antivirals for treatment of HIV infections, combinations. 
Farmakoterapevtska skupina: zdravila za sistemsko zdravljenje virusnih infekcij, zdravila za zdravljenje infekcij s HIV, kombinacije.
Inhibitors of OATP and BCRP include ciclosporin. 
Zaviralci OATP in BCRP vključujejo ciklosporin.
Adolescents aged 12 to < 18 years, ≥ 35 kg 
Mladostniki, stari 12 do < 18 let, ≥ 35 kg
In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. 
Pri nekaterih bolnikih z napredovalo okužbo s HIV (AIDSom) in oportunističnimi okužbami v zdravstveni zgodovini (okužbe, ki se pojavijo pri ljudeh z oslabljenim imunskim sistemom), se lahko znaki in simptomi vnetja zaradi prejšnjih okužb pojavijo kmalu po začetku zdravljenja HIV.
• neuroleptics/antipsychotics: pimozide, lurasidone 
• nevroleptiki/antipsihotiki: pimozid, lurasidon
Reduced susceptibility to elvitegravir is most commonly associated with the primary integrase mutations T66I, E92Q, and Q148R. 
Zmanjšana občutljivost za elvitegravir je najbolj pogosto povezana s primarnimi mutacijami integraze T66I, E92Q in Q148R.
Do not store the split tablet. 
Prepolovljenih tablet ne shranjujte.
Tenofovir alafenamide and tenofovir have a median plasma half-life of 0.51 and 32.37 hours, respectively. 
Tenofoviralafenamid in tenofovir imata mediani razpolovni čas v plazmi 0,51 oz. 32,37 ur.
Genvoya contains four active substances: 
Zdravilo Genvoya vsebuje štiri učinkovine:
At baseline, median eGFR was 56 mL/min. 
Na začetku je bila mediana eGFR 56 ml/min.
For elvitegravir, Cmax and AUC increased 22% and 36% with a light meal, and 56% and 91% with a high-fat meal, relative to fasting conditions. 
Za elvitegravir se je Cmax zvišal za 22 % in AUC za 36 % pri lahkem obroku in pri obroku z visoko vsebnostjo maščobe za 56 % oz. 91 % relativno glede na pogoje na tešče.
The European Medicines Agency has deferred the obligation to submit the results of studies with Genvoya in one or more subsets of the paediatric population in the treatment of human HIV-1 infection (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Genvoya za eno ali več podskupin pediatrične populacije za zdravljenje okužbe z virusom HIV-1 pri ljudeh (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
• If you are allergic to elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide or any of the other ingredients of this medicine (listed in section 6 of this leaflet). 
• Če ste alergični na elvitegravir, kobicistat, emtricitabin, tenofoviralafenamid ali katero koli sestavino tega zdravila (navedeno v poglavju 6 tega navodila).
EU/1/15/1061/001 30 film-coated tablets EU/1/15/1061/002 90 (3 bottles of 30) film-coated tablets 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/15/1061/001 30 filmsko obloženih tablet EU/1/15/1061/002 90 (3 plastenke po 30) filmsko obloženih tablet
One patient in the Genvoya group (1 of 22 [4.5%]) and 2 patients in the E/C/F/TDF group (2 of 20 [10%]) had reduced susceptibility to tenofovir. 
En bolnik v skupini z zdravilom Genvoya (1 od 22 [4,5 %]) in 2 bolnika v skupini E/C/F/TDF (2 od 20 [10 %]) sta imela zmanjšano občutljivost za tenofovir.
digoxin, disopyramide, flecainide, lidocaine, mexiletine, propafenone, metoprolol, timolol, amlodipine, diltiazem, felodipine, nicardipine, nifedipine and verapamil 
digoksin, dizopiramid, flekainid, lidokain, meksiletin, propafenon, metoprolol, timolol, amlodipin, diltiazem, felodipin, nikardipin, nifedipin in verapamil
Elvitegravir was negative in an in vitro bacterial mutagenicity test (Ames test) and negative in an in vivo rat micronucleus assay at doses up to 2,000 mg/kg. 
Elvitegravir je bil negativen v bakterijskem testu mutagenosti in vitro (Amesov test) in negativen v testu podganjih mikronukleusov in vivo pri odmerkih do 2.000 mg/kg.
• If you are intolerant to lactose (see Genvoya contains lactose later in this section). 
• Če ne prenašate laktoze (glejte odstavek Zdravilo Genvoya vsebuje laktozo v tem poglavju).
Viruses expressing the T66I/A mutations maintain susceptibility to raltegravir, while most other patterns showed reduced susceptibility to raltegravir. 
Virusi, ki izražajo mutacije T66I/A, ostanejo občutljivi na raltegravir, medtem ko je večina drugih vzorcev pokazala zmanjšano občutljivost za raltegravir.
Additional integrase mutations observed in cell culture selection included H51Y, F121Y, S147G, S153Y, E157Q, and R263K. 
Dodatne mutacije integraze, ki so jih opazili v izboru celične kulture, so vključevale H51Y, F121Y, S147G, S153Y, E157Q in R263K.
Cobicistat is an inhibitor of the following transporters: P-gp, breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1 and OATP1B3. 
Kobicistat je zaviralec naslednjih prenašalcev: P-gp, proteina rezistence pri raku dojke (BCRP- breast cancer resistance protein), transportnega polipeptida organskih anionov (OATP- organic anion transporting polypeptide), 1B1 in OATP1B3.
In an in vitro chromosomal aberration test, elvitegravir was negative with metabolic activation; however, an equivocal response was observed without activation. 
V testu kromosomske aberacije in vitro je bil elvitegravir negativen z aktivacijo presnove, vendar pa so brez aktivacije opazili dvoumen odziv.
At baseline, 80 patients (33%) had eGFRCG < 50 mL/min and 162 patients had eGFRCG ≥ 50 mL/min. 
Na začetku je imelo 80 bolnikov (33 %) eGFRCG < 50 ml/min in 162 bolnikov je imelo eGFRCG ≥ 50 ml/min.
As elvitegravir and cobicistat are highly bound to plasma proteins, it is unlikely that they would be significantly removed by haemodialysis or peritoneal dialysis. 
Ker se elvitegravir in kobicistat močno vežeta na plazemske proteine, ni verjetno, da bi ju hemodializa ali peritonealna dializa odstranila v pomembni meri.
Some patients taking combination antiretroviral medicines such as Genvoya may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). 
Pri nekaterih bolnikih, ki jemljejo kombinirana protiretrovirusna zdravila, kot je zdravilo Genvoya, se lahko pojavi bolezen kosti, imenovana osteonekroza (odmiranje kostnega tkiva kot posledica pomanjkanja oskrbe kosti s krvjo).
Most HIV-1 isolates from patients in both treatment groups who developed resistance mutations to elvitegravir developed resistance mutations to both emtricitabine and elvitegravir. 
Pri večini izolatov HIV-1 bolnikov v obeh skupinah zdravljenja, pri katerih so se razvile mutacije, povezane z rezistenco na elvitegravir, so se razvile mutacije, povezane z rezistenco tako za emtricitabin kot elvitegravir.
The mean plasma to blood drug concentration ratio was 1.37. 
Povprečno razmerje med koncentracijo zdravila v plazmi in krvi je bilo 1,37.
As the effect of cationic complexation of elvitegravir cannot be excluded when Genvoya is co-administered with multivitamin supplements, it is recommended to separate Genvoya and multivitamin supplements dosing by at least 4 hours. 
Ker učinkov kationske kompleksacije elvitegravira pri sočasni uporabi zdravila Genvoya ni mogoče izključiti, se priporoča, da se dajanje zdravila Genvoya in multivitaminskih dopolnil loči za vsaj 4 ure.
If you vomit less than 1 hour after taking Genvoya, take another tablet with food. 
Če bruhate manj kot 1 uro po zaužitju zdravila Genvoya, vzemite še eno tableto s hrano.
However, based on the information retrieved in literature and in the product information of integrase inhibitors containing medicinal products, it could be concluded that the following psychiatric disorders: depression, suicidal ideation and suicidal behaviour (particularly in patients with pre-existing history of psychiatric illness) are class-effect of integrase inhibitors and these are listed in the SmPC of other medicinal products containing integrase inhibitors in monotherapy and in fixed-dose combination (FDC). 
Vendar pa na podlagi informacij, pridobljenih v literaturi in v informacijah o zdravilih, ki vsebujejo zaviralce integraze, lahko sklepamo, da so naslednje psihiatrične motnje: depresija, samomorilne misli in samomorilno vedenje (zlasti pri bolnikih s predhodno anamnezo psihiatrične bolezni) učinek zdravil iz skupine zaviralcev integraze, in so navedene v povzetku glavnih značilnosti zdravila za druga zdravila, ki vsebujejo zaviralce integraze v obliki monoterapije in v obliki kombinacije fiksnih odmerkov (FDC).
Patients co-infected with HIV and HBV who discontinue Genvoya should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. 
Bolnike s hkratno okužbo s HIV in HBV, ki prekinejo zdravljenje z zdravilom Genvoya, je potrebno pozorneje opazovati in opravljati potrebne klinične in laboratorijske preiskave še vsaj nekaj mesecev po prenehanju zdravljenja.
Elvitegravir, cobicistat, and emtricitabine have all demonstrated low carcinogenic potential in mice and rats. 
Elvitegravir, kobicistat in emtricitabin so pokazali majhen kancerogeni potencial pri miših in podganah.
If you are on dialysis, take your daily dose of Genvoya following completion of dialysis. 
Če ste na dializi, vzemite svoj dnevni odmerek zdravila Genvoya po končani dializi.
If alternatives cannot be used, its use should only take place after medical evaluation and under close monitoring by your doctor for corticosteroid side effects. 
Kadar ni mogoče uporabiti drugih zdravil, se lahko uporabljajo le po zdravniškem pregledu in ob natančnem zdravniškem spremljanju zaradi možnosti pojava neželenih učinkov, povezanih s kortikosteroidi.
abnormal dreams 
nenavadne sanje
Interactions between the components of Genvoya and potential co-administered medicinal products are listed in Table 1 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”). 
Interakcije med učinkovinami zdravila Genvoya in možnimi sočasno uporabljenimi zdravili so navedene v preglednici 1 spodaj (povečanje je označeno z znakom “↑”, zmanjšanje z “↓”, brez spremembe z “↔”).
An assessment of benefit/risk ratio is recommended to justify use of voriconazole with Genvoya. 
Priporoča se ocena razmerja med koristmi in tveganji, ki bi upravičila uporabo vorikonazola z zdravilom Genvoya.
The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulfoxide diastereomers (~9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (~4% of dose). 
Biotransformacija emtricitabina vključuje oksidacijo tiolnega dela molekule, pri čemer nastanejo 3'-sulfoksid diastereomere (~9 % odmerka) in konjugacijo z glukuronsko kislino, pri čemer nastane 2'-O-glukuronid (~4 % odmerka).